viewHumanigen, Inc.

Humanigen study of monoclonal antibody in CAR-T therapy presented at Houston conference

The team reported enhanced anti-tumor activity, improved overall survival and improved durability of response with a reduced rate of relapse

A syringe
Findings were presented on behalf of a research team at Mayo Clinic in Rochester, Minnesota

Humanigen Inc (OTCMKTS:HGEN) said Monday that final results of a study on the use of GM-CSF neutralization in CAR-T therapy was presented last week at an annual meeting in Houston.

The Burlingame, California, company said in a statement that Rosalie Sterner presented results of the study on behalf of Dr Saad Kenderian and a research team at Mayo Clinic in  Rochester, Minnesota.

READ: Humanigen study of its monoclonal antibody in CAR-T therapy featured in medical journal

The study was conducted using lenzilumab, the company’s anti-GM-CSF (granulocyte-macrophage colony-stimulating factor) monoclonal antibody, and was recently featured on the cover of the February 14 edition of "blood", the journal of the American Society of Hematology.

The biotech’s lenzilumab monoclonal antibody is designed to reduce the sometimes dangerous side-effects associated with a cancer therapy involving altered T cells. 

Lenzilumab, used in combination with CAR-T therapy, prevents the onset of cytokine release syndrome and significantly reduces neuroinflammation, may prevent impairment of the blood-brain barrier and significantly reduces the neuroinflammation caused by CAR-T, according to Humanigen.

The team found that the therapy enhanced antitumor activity, improved overall survival and improved durability of response with a reduced rate of relapse observed with GM-CSF neutralization.

Shares of Humanigen were down $0.12 to $1.24 in Friday’s OTC Markets trading.

Contact Dennis Fitzgerald at [email protected]

Quick facts: Humanigen, Inc.

Price: 4.98 USD

Market: OTCQB
Market Cap: $629.18 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Humanigen, Inc. named herein, including the promotion by the Company of Humanigen, Inc. in any Content on the Site, the Company receives from...



Humanigen chosen by National Institute of Health's upcoming coronavirus...

Humanigen Inc (OTCQB:HGEN) CEO Cameron Durrant tells Proactive that its lead drug candidate lenzilumab was selected for use in the National Institute of Health’s upcoming coronavirus trial. Durrant says lenz will be evaluated in the National Institute of Allergy and Infectious Diseases’...

1 week, 1 day ago

2 min read